Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Threat Looms For J&J, Amgen And Others, Decision Resources Forecasts

This article was originally published in The Pink Sheet Daily

Executive Summary

J&J and Amgen are the drug makers that will lose the largest percent of cumulative revenues to biosimilars from 2009 to 2019, the research firm estimates.
Advertisement

Related Content

Biosimilars On The Horizon: How Much Will FDA Look To The East?
Biosimilars On The Horizon: How Much Will FDA Look To The East?
Opening A Door To Biosimilars In The US
On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era
On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era

Topics

Advertisement
UsernamePublicRestriction

Register

PS071174

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel